Abstract
Mutations in nucleophosmin (NPM) exon 12 and the resulting delocalization of NPM into the cytoplasm are the most specific and frequent cellular events in acute myeloid leukemia patients (AML) with normal karyotype. Cytoplasmatic NPM (NPMc+) is associated with responsiveness to chemotherapy and better prognosis. The activation of nuclear factor-κB (NF-κB) has been demonstrated to occur in a subset of AML patients and is thought to induce resistance to many chemotherapeutical agents. In this study, we demonstrate the increased in vitro sensitivity of NPMc+ cells to chemotherapeutical agents and their reduced NF-κB activity. Furthermore, we provide evidence of the interaction between NPMc+ and NF-κB in the cytoplasm, resulting in the sequestration and inactivation of NF-κB. The cytosolic localization and consequent inactivation of NF-κB justifies the reduced NF-κB DNA-binding activity observed in NPMc+ patients. These data, taken together, may provide a possible explanation for the increased rate of chemosensitivity observed among the NPMc+ patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
den Besten W, Kuo ML, Williams RT, Sherr CJ . Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 2005; 4: 1593–1598.
Cheng K, Grisendi S, Clohessy JG, Majid S, Bernardi R, Sportoletti P et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene 2007; 22: 7391–7400.
Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L et al. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res 15; 66: 3044–3050.
Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P, Zamponi R, Marine JC et al. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol 2005; 25: 8874–8886.
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281–1284.
Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ . The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996; 87: 882–886.
Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukaemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 12: 265–275.
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266.
Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733–3739.
Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106: 3747–3754.
Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106: 3740–3746.
Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005; 106: 2854–2861.
Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007; 110: 979–985.
Ghosh S, Karin M . Missing pieces in the NF-kB puzzle. Cell 2002; 109: 81–96.
Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S . NF-kB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia 2003; 18: 1–7.
Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301–2307.
Garg A, Aggarwal BB . Nuclear transcription factor-kB as a target for cancer drug development. Leukemia 2002; 16: 1053–1068.
Senftleben U, Karin M . The IKK/NF-kB pathway. Crit Care Med 2002; 30: 18–26.
Dhar SK, Lynn BC, Daosukho C, St Clair DK . Identification of nucleophosmin as an NF-kappaB co-activator for the induction of the human SOD2 gene. J Biol Chem 2004; 279: 28209–28219.
van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901–1928.
Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, Macleod RA et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005; 19: 1760–1767.
Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance. Leukemia 2007; 20: 61–67.
Falini B, Nicoletti I, Martelli MF, Mecucci C . Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007; 109: 874–885.
Aggarwall BB . Nuclear factor-kappaB: the enemy within cancer. Cancer Cell 2004; 6: 203–208.
Takebayashi T, Higashi H, Sudo H, Ozawa H, Suzuki E, Shirado O et al. NF-kappaB-dependent induction of cyclin D1 by retinoblastoma protein (pRB) family proteins and tumor derived pRB mutants. J Biol Chem 2003; 278: 14897–14905.
Karin M, Cao Y, Greten FR, Li ZW . NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301–310.
Karin M, Yamamoto Y, Wang QM . The IKK NF-κB system: a treasure trove for drug development. Nat Rev 2004; 3: 17–26.
Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2 induced apoptosis of human acute myeloid leukaemia cells. Blood 2005; 105: 804–811.
Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G . Nuclear factor kappakappaB as a target for new drug development in myeloid malignancies. Haematologica 2007; 92: 1224–1229.
Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al. Proteasome inhibitors: a novel class of potent and effective anti-tumor agents. Cancer Res 1999; 59: 2615–2622.
Acknowledgements
This work has been supported by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro), MURST-COFIN, AIL (Associazione Italiana contro le Leucemie) and Regione Piemonte.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cilloni, D., Messa, F., Rosso, V. et al. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-κB in AML carrying NPM1 mutations. Leukemia 22, 1234–1240 (2008). https://doi.org/10.1038/leu.2008.68
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.68
Keywords
This article is cited by
-
Cytoplasmic nucleophosmin has elevated T199 phosphorylation upon which G2/M phase progression is dependent
Scientific Reports (2015)
-
Analogue peptides for the immunotherapy of human acute myeloid leukemia
Cancer Immunology, Immunotherapy (2015)
-
Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology
Oncogene (2014)
-
NF-κB p65 repression by the sesquiterpene lactone, Helenalin, contributes to the induction of autophagy cell death
BMC Complementary and Alternative Medicine (2012)
-
Expression of Nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells
Journal of Biomedical Science (2012)